Boca Raton, Florida, Feb. 06, 2024 INmune Bio, Inc. , a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease with.
The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the.
The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the final
INmune Bio Inc. (INMB) said it received correspondence from the FDA confirming that the full clinical hold on the Alzheimer's disease clinical trial program has been lifted.